

2013 Publications (as of September 2013)

1. Hollenbeck BL, **Beckwith CG**. HIV-2 in Providence, Rhode Island from 2002-2011. *HIV Medicine* 2013 Feb;14(2):115-9.
2. Larney S, Kopinski H, **Beckwith CG**, **Zaller ND**, Des Jarlais D, Hagan H, **Rich JD**, **van den Bergh BJ**, Degenhardt J. The incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. *Hepatology* 2013. Epub ahead of print. March 15, 2013.
3. Kurth A, Kuo I, Peterson J, Azikiwe N, Bazerman L, Cates A, **Beckwith CG**. Information and Communication Technology to link Criminal Justice Reentrants to HIV Care in the Community. *AIDS Research and Treatment*, vol. 2013, Article ID 547381, 6 pages, 2013. doi:10.1155/2013/547381
4. Peterson J, Kuo I, Kurth A, Bazerman L, Cota M, Gray H, Azikiwe N, Cates A, **Beckwith CG**. Technology Use in Linking Criminal Justice Reentrants to HIV Care in the Community: A Qualitative Formative Research Study. Accepted for publication. *Journal of Health Communication*, September 2013.
5. Gardner A, Naurekas C, Losikoff P, **Beckwith C**, Martin C, **Carter EJ**. Experiences in Implementation of Routine HIV testing in a United States TB Clinic. *International Journal of Tuberculosis and Lung Disease* 2012; 16(9)1241-46(6).
6. Kalichman SC, Cheer C, White D, Jones Miche'l, Kalichman MO, Detorio MA, **Caliendo AM**, Schinazi RF. Use of dietary supplements among people living with HIV/AIDS is associated with vulnerability to medical misinformation on the internet. *AIDS Research and Therapy*. 2012; 9:1 doi:10.1186/1742-6405-9-1.
7. Kraft CS, Armstrong WS, **Caliendo AM**. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. *Clin Infect. Dis.* 2012;54:1793-7.
8. Kraft CS, Jacob JT, Sears MH, Burd EM, **Caliendo AM**, Lyon GM. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. *J. Clin Micro.* 2012;50:1061-3.
9. Anderson BL, Firnhaber C, Liuu T, Swarts A, Siminya M, Ingersoll J, **Caliendo AM**, **Cu-Uvin S**. Effect of trichomoniasis therapy on genital HIV viral burden among African American women. *Sex Transm Dis* 2012;39:638-42.
10. Crosby RA, Charnigo RA, Waethers C, **Caliendo AM** and Shrier LA. Condom effectiveness against non-viral sexually transmitted infections: a prospective study using electronic daily diaries. *Sex Transm Infect* 2012. In Press

11. Hayden R, Gu Z, Ingersoll J, Abdul-Ali D, Shi L, Pounds S and **Caliendo AM**. Comparison of Droplet Digital PCR to Real-Time PCR for Quantitative Detection of Cytomegalovirus. *Journal of Clinical Microbiology*. In Press
12. Kraft CS, Binongo JNB, Burd EM, Eaton ME, McCloskey CB, Fernandes H, Hill CE, and **Caliendo AM**. Successful use of Plasma Preparation Tubes™ (PPTs) in the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test. *J Clinical Virology*. In Press
13. Venkatesh KK, Mayer KH, **Carpenter CCJ**. Low-cost generic drugs under the president's emergency plan for AIDS relief drove down treatment cost; more are needed. *Health Affairs* 31(7), 1429-38, 2012, PMID: 22778332.
14. Klasen E, Miranda J, Khatry S, Menya D, Gilman R, Tielsch J, Kennedy C, Dreibeldis R, Naithani N, Kimaiyo S, Chiang M, **Carter EJ**, Sherman CB, Breyse P, Checkley W. Feasibility Intervention Trial of two types of improved cookstoves in three resource limited settings: study protocol for a randomized controlled trial. *Trials* 2013, 14: 327.
15. Szkwarko D, Ogaro F, Owiti P, **Carter EJ**. Implementing a Tuberculosis child contact register to quantify children at risk for tuberculosis and HIV in western Kenya. *Public Health Action* 2013; 3(3): 209-213.
16. Kirui N, Gardner A., Kamene J, Pastaki S., Mwangi A, **Carter EJ**. Important co-morbidity in patients with diabetes mellitus in three clinics in western Kenya. *Public Health Action* 2012; 2(4):148-151.
17. Siika A, Yiannoutsos Y, Wools-Kalustian K, Musick B, Mwnagi A, Diero L, kimaiyo S, Tierney, **Carter EJ**, Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy. *Plos One* e%3022 January 2013 VI 8 No 1
18. Omentia D, Park P, Gardener A, Kisang G, Dieto L, Sitienei, **Carter EJ**. Community Based Treatment of Multi Drug Resistant Tuberculosis; Early Experience and Results from western Kenya. *Public Health Action* 2012; (2)2:38-42.
19. Bloomfield G. Lagat D, Akwanalo C, **Carter EJ**, Lugogo N, Vedanthan R, Velasquez and Right Heart Failure in Persons Exposed to Household Air Pollution in LMIC. 2012 *Global Heart* 7(3): 249-259.
20. Shaffer D, Obiero E, Bett J, Kiptto I, Maswai J, Sawe F, **Carter EJ**. Successes and challenges in an Integrated Tuberculosis/HIV Clinic in a Rural Resource Limited Setting: Experiences from Kericho, Kenya. *AIDS Research and Treatment*. Volume 2012. Article ID 238012, 8 pages <http://dx.doi.org/10.1155/2012/238012>
21. **Chan PA**, Huang A, DeLong AK, Hogan JW, Salemi M, Mayer KH, Operario D, **Kantor R**. (2013) "Molecular phylogenetic investigation of local HIV transmission reveals complex network dynamics among men who have sex with men." (in press)
22. **Chan PA**, S Kazi, **Rana A**, I Blazar, CC DeJong, KH Mayer, TK Huard, K Carleton, **Gillani F**, N Alexander, Z Parillo, **Flanigan TP**, **Kantor R**. New HIV infections at Southern New England

academic institutions: Implications for prevention. *AIDS Research and Human Retroviruses* 2013;29:2013: 25-29. PMID 3537304

23. Sison N, Yolken A, Poceta J, Mena L, **Chan PA**, Barnes A, Smith E, **Nunn A**. (2013) "Healthcare Provider Attitudes, Practices, and Recommendations for Enhancing Routine HIV Testing and Linkage to Care in the Mississippi Delta Region." *AIDS Patient Care STDs*, 27(9):511-7.
24. Grin B, **Chan PA**, Operario D. (2013) "Knowledge of Acute HIV Infection Among Gay and Bisexual Male College Students." *The Journal of American College Health*, 61(4):232-41.
25. Echenique IA, **Chan PA**, Chapin KC, Andrea SB, Fava JL, **Mermel LA**. Clinical characteristics and outcomes in hospitalized patients with respiratory viral co-infection during the 2009 H1N1 influenza pandemic. *PLoS One*. 2013;8(4):e60845.
26. NE Alexander, **Chan PA**, T Rogo, Z Parillo, C Browning, B Isabell, C Calcione, S Chowdhury, P Simon, **Kantor R**. Interrupting Transmission of HIV and other Sexually Transmitted Infections in Rhode Island. *Medicine and Health RI* 2012;95:241-244. PMID 22970465
27. **Chan PA**, Huang A, **Kantor R**. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: Implications for pre-exposure prophylaxis. *Journal of the International AIDS Society* 2012;15:17701-5. PMID 3494163
28. **Chan PA**, Janvier M, Alexander NE, **Kojic EM**, Chapin K. Recommendations for the diagnosis of *Neisseria gonorrhoeae* and *Chlamydia trachomatis*, including extra-gene sites. *Med Hlth RI* 2012; Aug;95(8):252-4, PMID 22970467.
29. **Coetzer M**, B Westley, A DeLong, T Chhراing, S Dim, E Nerrienet, L Schreier, Hogan J, **Kantor R**. Extensive Drug Resistance in HIV-Infected Cambodian Children Failing First-Line Antiretroviral Therapy is Undetected by WHO 2010 Guidelines. *AIDS Research and Human Retroviruses* 2013 [Epub 3/19/13] PMID 23506238
30. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis T, Carneiro H, Glavis-Bloom J, **Coleman JJ**, **Mylonakis E**. Fusarium infection: Report of 26 cases and review of 97 cases from the literature. *Medicine*. (in press)
31. Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M, Demas V, Skewis LR, Anagnostou T, **Coleman JJ**, Wellman P, **Mylonakis E**, Lowery TJ. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. *Sci Transl Med*. 2013;5(182):182ra54. PMID: 23616121
32. Fiscus SA, **Cu-Uvin S**, Eshete AT, Hughes MD, Bao Y, Hosseinipour M, Grinsztejn B, Badal-Faesen S, Dragavon J, Coombs RW, Braun K, Moran L, Hakim J, **Flanigan TP**, Kumarasamy N, Campbell TB; for the A5185s Team. Changes in HIV-1 Subtypes B and C Genital Tract

RNA in Women and Men After Initiation of Antiretroviral Therapy. *Clin Infect Dis*. 2013 Apr 16. [Epub ahead of print] PMID:23532477

33. Anderson BL, Ghosh M, Raker C, Fahey J, Song Y, Rouse DJ, Wira CR, **Cu-Uvin S**. In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women. *Am J Obstet Gynecol*. 2013 Apr;208(4):321.e1-9.PMID: 22727351
34. Venkatesh KK, **Cu-Uvin S**. Assessing the Relationship Between Cervical Ectopy and HIV Susceptibility: Implications for HIV Prevention in Women. *Am J Reprod Immunol*. 2013 Feb;69 Suppl 1:68-73 PMID: 23057756
35. Anderson JR, Cohan D, **Cu-Uvin S**. HIV and reproduction: fertility, contraception, and preconception issues and interventions. *Infect Dis Obstet Gynecol*. 2012;2012:736864. doi: 10.1155/2012/736864. Epub 2012 Dec 30. PMID:23345960
36. Matthews LT, Smit JA, **Cu-Uvin S**, Cohan D. Antiretrovirals and safer conception for HIV-serodiscordant couples. *Curr Opin HIV AIDS*. 2012 Nov;7(6):569-578.PMID:23032734
37. Drolet, BC, Schwede BA, Bishop KD, **Fischer SA**. Compliance and Falsification of Duty Hours: Reports from Residents and Program Directors. *Journal of Graduate Medical Education*. September 2013 (368-73).
38. Lu K, **Fischer SA**, Avery RK, and the AST Infectious Disease Community of Practice. Screening of Donor and Recipient Prior to Solid Organ Transplantation. *American Journal of Transplantation*. 2013;13 (s4): 9-21.
39. Daniels AH, McDonnell M, Born CT, Hayda RA, Ehrlich MG, Trafton PG, **Fischer SA**, DiGiovanni CW. Critical analysis of a trauma fellowship-modeled, six-year orthopaedic surgery training program. *J Bone Joint Surg Am* 2013;95:e108 (1-8).
40. Christino MA, Matson AP, **Fischer SA**, et al. Paperwork versus patient care: a nationwide survey of residents' perceptions of clinical documentation requirements and patient care. *Journal of Graduate Medical Education*. In press
41. Drolet BC, Anandarajah G, **Fischer SA**. The impact of 2011 duty hours requirements on family medicine residents. *Family Medicine*. In press
42. Bariteau, JT, Waryasz, GR, **Fischer SA**. Fungal Osteomyelitis and Arthritis, *Journal of the American Academy of Orthopedic Surgeons*. In Press.
43. Daniels, A, DePasse, J, **Fischer SA**. The Current State of US Spine Surgery Training: a Survey of Residency and Spine Fellowship Program Directors, *Journal of Neurosurgery: Spine*. In Press

44. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, Swaminathan S, **Flanigan TP**, Walensky RP, Freedberg KA. Clinical Impact and Cost-Effectiveness of Expanding Voluntary HIV Testing in India. (2013) *PLoS One* May 31;8(5):e64604. doi: 10.1371/journal.pone.00694604. Print 2013. PMID: 23741348 PMCID: PMC3669338
45. Stein MS, Spaulding AC, Cunningham M, Messina LC, Kim BI, Chung KW, Draine J, Jordan AO, Harrison A, Avery AK, **Flanigan TP**. HIV-Positive and in Jail: Race, Risk Factors, and Prior Access to Care. (2012) *AIDS Behav* Oct 20. (Epub ahead of print) PMID: 23086426
46. Spaulding AC, Messina LC, Kim BI, Chung KW, Lincoln T, Teixeira P, Avery AK, Cunningham M, Stein MS, Ahuja D, **Flanigan TP**. Planning or Success Predicts Virus Suppressed: Results of a Non-Controlled Observational Study of factors Associated with viral Suppression among HIV-Positive Persons Following Jail Release. (2012) *AIDS Behav.* Oct 18. (Epub ahead of print) PMID: 23076719
47. Kuester LB, **Flanigan TP**, Clarke JG, Fletcher A. Risk factors for non-communicable diseases in Prison populations. (2012) *Lancet* Oct 6; 380(9849):1226-7; author reply 1227-8. PMID: 23040852
48. Kumarasamy N, Venkatesh KK, Vignesh R, Devaleenal B, Poongulali S, Yepthomi T, **Flanigan TP**, Benson C, Mayer KH. Clinical Outcomes among HIV-Tuberculosis Coinfected Patients Developing Immune reconstitution Inflammatory Syndrome after HAART Initiation in South India. (2012) *J Int Assoc Physicians AIDS Care (Chic)* Sep 24 (Epub ahead of print) PMID: 23011868
49. Campbell TB, Smeaton LM, Kumarasamy N, **Flanigan TP**, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AL, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, DeGruttoia V, Hakim JG; PEARLS study team of the ACTG. Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1; A Randomized Clinical Trial in Diverse Multinational settings. (2012) *PLoS Med* 9(8); e1001290. /Epub 2012 Aug 14. PMID: 22936892. PMCID: PMC3419182
50. Kato IT, Prates RA, Sabino CP, **Fuchs BB**, Tegos GP, **Mylonakis E**, Hamblin MR, Ribiero MS. Antimicrobial photodynamic inactivation inhibits *Candida albicans* virulence factors and reduces in vivo pathogenicity. *Antimicrob Agents Chemother.* 2013; 57(1): 445-451. PMC3535901
51. Prates RA, **Fuchs BB**, Mizuno K, Naqvi Q, Kato IT, Ribiero MS, **Mylonakis E**, Tegos GP, Hamblin MR. Effects of virulence factors on the photodynamic inactivation of *Cryptococcus neoformans*. *PLoS ONE* 2013; 8(1): e54387. PMC3548784
52. Chibebe Junior J, **Fuchs BB**, Sabino CP, Junqueira JC, Jorge AO, Ribiero MS, Gilmore MS, **Rice LB**, Tegos GP, Hamblin MR, **Mylonakis E**. Photodynamic and antibiotic therapy

impair the pathogenesis of *Enterococcus faecium* in a whole animal insect model. *PLoS ONE* 2013; 8(2): e55926. PMC3573038

53. Chibebe Junior J, Sabino CP, Tan X, Junqueira JC, Wang Y, **Fuchs BB**, Jorge AO, Tegos GP, Hamblin MR, **Mylonakis E**. Selective photoinactivation of *Candida albicans* in the non-vertebrate host infection model *Galleria mellonella*. *BMC Microbiol.* 2013; 13(1):217.
54. Kourkoumpetis T, **Fuchs B**, **Coleman JJ**, Desalermos A, **Mylonakis E**. PCR-based assays for the diagnosis of invasive fungal infections. *Clin Infect Dis.* 2012;54(9):1322-31.
55. Leeper S, Fillion K, **Gillani F**, Ross H, **Rana A**, **Tashima K**. Decade of HIV in Rhode Island: Demographic and clinical characteristics of patients diagnosed in 2001 and 2010. (2013) *R I Med J.* 96(2):35-39.
56. Heffernan, D.S., S.F. Monaghan, R.K. Thakkar, M.L. Tran, C.S. Chung, **Gregory SH**, W.G. Cioffi, and A. Ayala. 2013. Inflammatory mechanisms in sepsis: elevated invariant natural killer T-cell numbers in mouse and their modulatory effect on macrophage function. *Shock* 40:122-128.
57. Self, A.A., P.T. Losikoff, and **Gregory SH**. 2013. Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C. *Hum.Vaccin.Immunother.* 9:1569-1576.
58. Duwaerts, C.C., S. Gehring, C.W. Cheng, N. van Rooijen, and **Gregory SH**. 2013. Contrasting responses of Kupffer cells and inflammatory mononuclear phagocytes to biliary obstruction in a mouse model of cholestatic liver injury. *Liver Int.* 33:255-265.
59. Losikoff, P.T., A.A. Self, and **Gregory SH**. 2012. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. *Virulence.* 3:610-620.
60. Duwaerts, C.C., E.P. Sun, C-W. Cheng, N. van Rooijen and **Gregory SH**. 2013. Cross-activating invariant NKT cells and Kupffer cells suppress cholestatic liver injury in a mouse model of biliary obstruction. *PLoS One* (in press).
61. Chen J, Yu B, Wang Y, Tang M, Hu Y, Cai T,, Zhang F, von Zinkernagel D, **Harwell JI**, Huang ZJ. Expansion of HIV care and treatment in Yunnan Province, China: Treatment outcomes with scale up of combination antiretroviral therapy. *AIDS Care* 2013.
62. Sughandi N, **Harwell JI**. Children with HIV in low-prevalence settings: finding the needle in a haystack. *Clin Infect Dis* 2013;56:745-6.
63. **Kantor R**, Chapman S, Ingersoll J, Kurpewski J, De Pasquale M, D'Aquila R, **Caliendo AM** and **Cu-Uvin S**. Persistent genital tract HIV-1 RNA shedding after change in treatment

regimens in Antiretroviral-experienced women with detectable plasma viral load.
Journal of Women's Health. In Press

64. A DeLong, M Wu, J Wu, Hogan J, **Kantor R**. SQUAT (Sequence Quality Assessment Tool): A standalone computational tool for HIV sequence quality evaluation. *AIDS Research and Human Retroviruses* 2012;28:894-901. PMID 3399557
65. Huang A, J Hogan, S Istrail, A DeLong, D Katzenstein, **Kantor R**. Global Analysis of Sequence Diversity Within HIV-1 Subtypes Across Geographic Regions. *Future Virology* 2012;7:505-17. PMID 3400699
66. S Saravanan, V Madhavan, SS Solomon, **Kantor R**, D Katzenstein, S Sivamalar, N Kumarasamy, DM Smith, KH Mayer, S Solomon, P Balakrishnan. Reverse Transcriptase Substitution at Codons 208 and 228 Among Treatment-experienced HIV-1 Subtype-C Infected Indian Patients Is Strongly Associated with Thymidine Analogue Mutations. *Journal of AIDS*, 2012;59:e26-7. PMID 3259528
67. S Saravanan, M Vidya, **Kantor R**, S Sivamalar, S Gomathi, SS Solomon, N Kumarasamy, DM Smith, RT Schooley, S Solomon, P Balakrishnan. Unusual Insertion and Deletion at Codon 67 and 69 of HIV Type 1 Subtype C Reverse Transcriptase Among First-Line Highly Active Antiretroviral Treatment-Failing South Indian Patients: Association with Other Resistance Mutations. *AIDS Research and Human Retroviruses* 2012; 28:1763-5. PMID 3505055
68. B Westley, AK DeLong, CS Tray, D Sophearin, EM Dufort, E Nerrienet, L Schreier, JI Harwell, **Kantor R**. Prediction of Treatment Failure using 2010 WHO Guidelines is Associated with High Misclassification Rates and Drug Resistance among HIV-Infected Cambodian Children. *Clinical Infectious Diseases*, 2012;55:432-440. PMID 3491779
69. Huang A, **Kantor R**, A DeLong, L Schreier, S Istrail. QColors: An Algorithm for Conservative Viral Quasispecies Reconstruction from Short and Non-Contiguous Next Generation Sequencing Reads. In *Silico Biology* 2012;11:193-201. PMID 23202421
70. A Jiamsakul, **Kantor R**, PCK Li, S Sirivichayakul, T Sirisanthana, P Kantipong, CKC Lee, A Kamarulzaman, W Ratanasuan, R Ditangco, T Singtoroj, S Sungkanuparph Comparison of Predicted Susceptibility between Genotype and Virtual Phenotype HIV Drug Resistance Interpretation Systems among Treatment-naive HIV-infected Patients in Asia: TASER-M Cohort Analysis. *BMC Research Notes* 2012;5:582-591. PMID 3505153
71. S Saravanan, V Madhavan, P Balakrishnan, DM Smith, SS Solomon, S Sivamalar, S Poongulali, N Kumarasamy, RT Schooley, S Solomon, **Kantor R**. Darunavir is a good third-line antiretroviral agent for HIV-1 infected patients failing second-line protease inhibitor-based regimens in South India. *AIDS Research and Human Retroviruses* 2012;29:630-2. PMID 23045961

72. KK Venkatesh, AK DeLong, **Kantor R**, S Chapman, J Ingersoll, J Kurpewski, MP De Pasquale, R D'Aquila, AM. Caliendo, **Cu-Uvin S**. Antiretroviral-experienced women with detectable plasma viral load continue to have genital tract HIV-1 RNA shedding after change in treatment regimens. *Journal of Women's Health* 2013;22:1-9. PMID 23531097
73. K Morabito, **Kantor R**, L Schreier, A Tripathi. Detection of HIV-1 Minority Variants Containing the K103N Drug-Resistance Mutation Using a Simple Method to Amplify RNA Targets (SMART). *Journal of Molecular Diagnostics* 2013;15:401. PMCID 3644729
74. S Land, J Zhou, P Cunningham, A Sohn, T Singtoroj, D Katzenstein, M Mann, D Sayer, **Kantor R**. Capacity building and predictors of success for HIV drug resistance testing in the Asia Pacific Region and Africa. *Journal of the International AIDS Society* 2013;16:18580-18589. PMCID: PMC3709369
75. M Mann, L Diero, E Kemboi, F Mambo, W Injera, A DeLong, L Schreier, K Wools Kaloustian, N Buziba, **Kantor R**. Unplanned Antiretroviral Treatment Interruptions Induced by the Kenyan Post-Election Crisis are Associated with HIV virologic Failure. *Journal of AIDS* 2013;64:220-224.
76. T Liu, JW Hogan, L Wang, S Zhang, **Kantor R**. Optimizing diagnosis of HIV treatment failure in resource limited settings with selective gold standard viral load testing (in press, *Journal of the American Statistics Association*).
77. S Sungkanuparph, A Jiamsakul, S Kiertiburanakul, S Sirivichayakul, J Praparattanapan, **Kantor R**; on behalf of the TREAT Asia Studies to Evaluate Resistance. Rilpivirine Resistance-Associated Mutations Among Antiretroviral-Naive Patients Infected With HIV-1 in Asia. *Journal of Acquired Immune Deficiency Syndromes* 2013; 62:98–100.
78. M Mann, MN Lurie, S Kimaiyo, **Kantor R**. Effects of Political Conflict Induced Treatment Interruptions on HIV Drug Resistance. *AIDS Reviews* 2013;15:15-24, 2013. PMID 23449225
79. **Kantor R**. Research Components of the Brown Kenya Program: A Personal and Professional Perspective. *RI Medical Journal* 2013;96:16-19. PMID 24087816
80. **Knoll BM, Mylonakis E**. Antibacterial Bio-Agents based on principles of bacteriophage biology - an Overview. *Clin. Inf Dis* (in press).
81. **Knoll BM**, Spieler PJ, Kubiak DW, Marty FM. Neutropenia Associated with Prolonged Daptomycin Use. *Clin Infect Dis*. 2013 May;56(9):1353-4.
82. **Knoll BM**, Koo S, Issa NC, Hammond SP, Tullius SG, Baden LR, Pomahac B, Marty FM. Infections following Facial Composite Tissue Allotransplantation. Single Center Experience and Review of the Literature. *Am J Transplant*. 2013 Mar;13(3):770-9.

83. **Knoll BM**, Hellmann M, Kotton CN. Vancomycin-resistant *Enterococcus faecium* meningitis in adults: Case series and review of the literature. *Scand J Infect Dis*. 2013 Feb;45(2):131-9.
84. **Knoll BM**, Kappagoda S, Gill RR, Goldberg HJ, Boyle K, Baden LR, Fuhlbrigge AL, Marty FM. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. *Transpl Infect Dis*. 2012 Oct;14(5):452-60.
85. Morrow KM, Fava JL, Rosen RK, Vargas S, Shaw JG, **Kojic EM**, Kiser PF, Friend DR, Katz D. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: Relating user perceptions and experiences to formulation properties. *AIDS Res Hum Retroviruses* 2013; Nov 4 [Epub ahead of print] PMID:24180360.
86. **Kojic EM**. Human papillomavirus (HPV) and trichomonas: common, concerning, and challenging sexually transmitted infections. *Med Hlth RI* 2012; Aug;95(8):255-7, PMID:22970468.
87. Wilhelm AK, Paci G, Lartey M, **Kwara A**. Treatment default among patients initiating HAART at Korle-Bu Teaching Hospital in Accra, Ghana. *West Afr J Med* 2012;31:264-9.
88. **Kwara A**, Cao L, Yang H, Poethke P, Kurpewski J, **Tashima KT**, Mahjoub BD, Court MH, Peloquin CA. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. *Pharmacotherapy* 2013, doi: 10.1002/phar.1388
89. Hosek, S, Siberry G, Bell M, **Lally M**, et al. Project PrEPare (ATN082): The Acceptability and Feasibility of an HIV Pre-Exposure Prophylaxis (PrEP) Trial with Young Men who Have Sex with Men (YMSM). *J of Acquired Immune Deficiency Syndromes* [Epub 12/6/12] PMID23221985
90. Ott MA, Alexander AB, **Lally M**, Steever JB, Zimet GD, and the Adolescent Trials Network for HIV/AIDS Interventions. Preventive Misconception and Adolescents' Knowledge about HIV Vaccine Trials. *Journal of Medical Ethics*, [Epub 1/25/13]. PMC3677956
91. Lacourse S, Rybak N, Lewis C, Gartman J, **Larkin J**, McLaughlin S, Toll ET. Health screening of newly resettled refugees in a primary care setting. *R I Med J* (2013). Apr 1;96(4):28-32.
92. Angione SL, Sarma AA, **Mermel LA**, Tripathi A. A novel subtyping assay for detection of *Clostridium difficile* virulence genes. *J Mol Diagn* (in press).
93. **Mermel LA**. What is the evidence for intraluminal colonization of hemodialysis catheters? *Kidney Int* (in press).

94. Baier R, Morphis B, Marsella M, **Mermel LA**. Clostridium difficile surveillance: a multicenter comparison of LabID events and use of standard definitions. *Infect Control Hosp Epidemiol*. 2013;34(6):653-5.
95. Kowitt B, Jefferson J, **Mermel LA**. Factors associated with hand hygiene compliance at a tertiary care teaching hospital. *Infect Control Hosp Epidemiol*. 2013;34(11):1146-52.
96. **Mermel LA**, Jefferson J, Blanchard K, Parenteau S, Mathis B, Chapin K, Machan JT. Reducing Clostridium difficile incidence, colectomies, and mortality in the hospital setting: a successful multidisciplinary approach. *Jt Comm J Qual Patient Saf*. 2013;39(7):298-305.
97. Gordon LB, Waxman MJ, Ragsdale L, **Mermel LA**. Overtreatment of presumed urinary tract infection in older women presenting to the emergency department. *J Am Geriatr Soc*. 2013;61(5):788-92.
98. **Mermel LA**. Testing, testing, testing. When will the madness stop? *Med Health RI* 96:13, 2013.
99. **Mermel LA**. Infection prevention and control during prolonged human space travel. *Clin Infect Dis*. 2013 Jan;56(1):123-30. Erratum in: *Clin Infect Dis*. 2013;56(11):1684.
100. Karlik JB, Duron V, **Mermel LA**, Mazzaglia P. Severe group a streptococcus surgical site infection after thyroid lobectomy. *Surg Infect (Larchmt)*. 2013;14(2):216-20.
101. Hardy EE, **Mermel LA**, Chapin KC, Gupta E, Vanner C. Detection of a New Delhi metallo-beta-lactamase in Klebsiella pneumoniae in two patients – Rhode Island, March 2012. *MMWR Morb Mortal Wkly Rep* 61:446-448, 2012.
102. Parienti JJ, du Cheyron D, Timsit JF, Traoré O, Kalfon P, Mimoz O, **Mermel LA**. Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults. *Crit Care Med*. 2012;40(5):1627-34.
103. LaPlante KL, Woodmansee S, **Mermel LA**. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions. *Am J Health Syst Pharm*. 2012;69(16):1405-9.
104. Novikov A, Lam MY, **Mermel LA**, Casey AL, Elliott TS, Nightingale P. Impact of catheter antimicrobial coating on species-specific risk of catheter colonization: a meta-analysis. *Antimicrob Resist Infect Control*. 2012;1(1):40. doi: 10.1186/2047-2994-1-40.
105. **Montague BT**, Kahler C, Colby S, McHugh K, Squires D, Fitzgerald B, Operario D, Gallagher D, Monti P, Mayer K. Attitudes and training needs of New England HIV care and addiction treatment providers: opportunities for better integration of HIV and alcohol treatment services. *Addictive Disorders and their treatment* (in press).

106. Winston SE, **Montague BT**, Lopez MJ, Delong A, LeMarchand C, Bedoya A, **Gillani FS**, **Beckwith CG**. Evaluation of longitudinal clinical outcomes and adherence to care among HIV-infected refugees. *Journal of the International Association of Physicians in AIDS Care* 2013; 12 (3): 202-207.
107. Lee J, Reece R, **Montague BT**, **Rana A**, **Flanigan TP**. The Future of Generic Drugs in Rhode Island. *RI Med J*. 2013 Sep 6; 96(9):30-3. PMID: 24015398
108. **Montague B**, Rosen D, Solomon L, Nunn A, Green T, Costa M, Baillargeon J, Wohl D, Paar DP, **Rich JD** and the LINC Group. Tracking linkage to HIV care for former prisoners: a public health priority. *Virulence* 3(3):319-24, 2012. PMCID: PMC3442844
109. Arvanitis M, **Mylonakis E**. *C. elegans* for anti-infective discovery. *Curr Opin Pharmacol*. 2013;13(5):769-774.
110. Arvanitis M, Glavis-Bloom J, **Mylonakis E**. Invertebrate models of fungal infection. *Biochim Biophys Acta*. 2013;1832(9):1378-83. PMID:23517918.
111. Anagnostou T, Arvanitis M, Kourkoumpetis T, Desalermos A, Carneiro H, **Mylonakis E**. Nocardiosis of the central nervous system: Experience from a general hospital and review of 84 cases. *Medicine*. (in press)
112. Li DD, Xu Y, Zhang D, Quan H, **Mylonakis E**, Hu DD, Li MB, Zhao LX, Zhu LH, Wang Y, Jiang YY. Fluconazole assists berberine to kill fluconazole-resistant *Candida albicans*. *Antimicrob Agents Chemother*. (in press)
113. Wang Y, Li DD, Jiang YY, **Mylonakis E**. Utility of insects for studying human pathogens and evaluating new antimicrobial agents. *Adv Biochem Eng Biotechnol* (in press).
114. Diaz JA, Fabre V, **Neill MA**. *Sexually Transmitted Diseases in Primary Care*. *Medicine Health RI*. 2012; 95:236-240.
115. Slama T, Kauffman CA, Patterson TF, **Neill MA**. Fungal outbreak update from IDWeek. *Clin Infect Dis* 2012 (doi: 10.1093/cid/cis925) Available at:<http://cid.oxfordjournals.org/content/early/2012/11/02/cid.cis925>
116. Sison, N., Yolken A., Poceta J., Mena L., Chan P., Barnes A., Smith E., **Nunn A**. Healthcare Provider Attitudes, Practices and Recommendations for Enhancing Routine HIV Testing and Linkage to Care in the Mississippi Delta Region. 2013 Sep;27(9):511-7, *AIDS Patient Care and STDS*.
117. **Nunn A**. Yolken A., Cutler B, Trooskin S, Wilson P, Little S, Mayer K. Geography Shouldn't be Destiny: Focusing HIV/AIDS implementation research and programs on microepidemics in American neighborhoods. Accepted, *American Journal of Public Health*, August 2013.

118. **Nunn A.** Dickman, S., Natrass, N., Cornwall A., Gruskin, S. The Impacts of AIDS Movements on the Policy Responses to HIV/AIDS in Brazil and South Africa: A Comparative Analysis. *Global Public Health*, Feb 4 2013 (ePub ahead of print).
119. **Nunn A**, Cornwall A, Thomas G, Callahan PL, Waller PA, Friend R, Broadnax PJ, **Flanigan TP**. What's God got to do with it? Engaging African-American faith-based institutions in HIV prevention. (2013) *Glob Public Health.*;8(3):258-69. doi: 10.1080/17441692.2012.759608. Epub 2013 Feb 4. PMID: 23379422 PMCID: PMC3601577
120. **Nunn A.** Cornwall, A., Chute, N., Sanders, J., Thomas, G., James, G., **Lally M**, Trooskin, S., **Flanigan TP**. Keeping the Faith: African American Faith Leaders' Perspectives and Recommendations for Reducing Racial Disparities in HIV/AIDS Infection. *PLoS ONE*, 7(5):e36172, 2012.
121. **Nunn A, Rich JD.** Commentary on Boyd et al (2012): debunking myths about methadone and crime. *Addiction* 107(9):1639-40, 2012.
122. Vincent J-L, **Opal SM**, Marshall J, Tracey K. Definitions for sepsis: Time for a change. *Lancet* 2013; 381:774-775.
123. Hurley JC, **Opal SM**. Prognostic value of endotoxemia in patients with gram-negative bacteremia is species dependent: an individual patient data meta-analysis. *Journal of Innate Immunity* 2013; (in press)
124. Ramachandran G, Tulapurkar ME, Harris KM, Arad G, Shivran A, Shemesh R, De Tolla LJ, Benazzi C, **Opal SM**, , Kaempfer R, Cross AS. A peptide antagonist of CD 28 signaling attenuates toxic shock and necrotizing soft tissue infection induced by *Streptococcus pyogenes*. *Journal of Infectious Diseases* 2013; 206(12):1869-1877.
125. Dellinger P, Levy MM, Rhodes A, Annane D, Gerlach H, **Opal SM**, Servansky J, Sprung CL, Douglas IS, Jaeschke R, Osborn T, Nunnally M, Townshead SR, Reinhart K, Kleinpell R, Angus D, Deutschman CS, Machado F, Rubenfeld, G, Webb S, Beale R J, Vincent J-L, Moreno R, for the surviving sepsis campaign guidelines committee. The surviving sepsis guidelines: 2012. *Critical Care Medicine* 2013;41(2):580-637.
126. Fedson D, **Opal SM**. The continuing controversy over H5N1 influenza virus transmissibility research: An opportunity for a practical response to a global threat. *Influenza and Respiratory Viruses* 2013; 9(5):1-10.
127. Sim T, Browne SK, Holland S, Vigliani M, Zachary D, Rosen L, **Opal SM**. Recurrent *Burkholderia gladioli* suppurative lymphadenitis associated with neutralizing anti-IL-12 auto antibodies. *Journal of Clinical Immunology* 2013;33(6):1057-1061.
128. **Opal SM**, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugenier T, Parrotin D, Tidswell M, Tillis T, Jaurequi A, Krell E, Pacht Y, Takahashi H, Peckelsen A,

- Cordasco D, Chang C, Oeye E, Aikawa N, Maruyama T, Schein R, Kalil A, Van Nuffelen M, Lynn M, Rossignol D, Gogate J, Roberts M, Wheeler J, Vincent J-L, and the ACCESS Study Group: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized study. *Journal of the American Medical Association* 2013;309(11): 1154-1162.
129. **Opal SM**, Dellinger RP, Vincent JL, Angus D, Masur H. The next generation of sepsis trials: a critical reassessment after the demise of human recombinant activated protein C. *Critical Care Medicine* 2013;41 (in press)
130. Artenstein A, Higgins T, **Opal SM**. Sepsis and scientific revolutions. *Critical Care Med* 2013; 41: (in press).
131. Bulger EM, Maier RV, Sperry J, Joshi M, Henry S, Moore FA, Moldower LL, Demetriades D, Talvig P, Schreiber M, Ham B, Cohen M, **Opal SM**, Segalovich I, Maislin G, Hoffman Y, Shirvan A. A Novel Drug for Treatment of Necrotizing Soft Tissue Infections: Results of a Phase 2a Randomized Controlled Trial of AB103, a CD28 Co-stimulatory Receptor Modulator. *JAMA Surgery* (in press).
132. Wang J, Tai W, Angione S, John A, **Opal SM**, Artenstein A, Tripathi A. Subtyping Clinical Isolates of Influenza A Virus using a Simple Method to Amplify RNA Targets (SMART). *Journal of Clinical Microbiology* 2013; 51(10):3324-3320.
133. Wittebole X, DeRoocke S, **Opal SM**. Bacteriophage therapy as a novel treatment for multidrug resistant pathogens. *Virulence* 2013; 4 (8): 1-10.
134. Angione S, Inde Z, Beck C, Artenstein A, **Opal SM**, Tripathi A. Microdroplet sandwich real-time RT-PCR for detection of pandemic and seasonal influenza subtypes. *PLoS ONE* 2013;8(9)13: e73497.
135. LaRosa S, **Opal SM**. Sepsis and septic shock. American College of Physicians Medicine. Infectious Disease. *ACP Medicine* (Online). 2013; 10: (in press)
136. **Opal SM**, LaRosa SP. Recombinant Human Activated Protein C as a Therapy for Severe Sepsis: Lessons learned. *American Journal of Respiratory and Critical Care Medicine*. 2013; 187:1041-1043.
137. **Opal SM**. McCulloh R. (editorial) Human recombinant lactoferrin for adult sepsis: Too good to be true? *Critical Care Medicine* 2013; 41(3): 908-909.
138. Vincent J-L, **Opal SM**, Marshall J, Tracey K. Sepsis definitions-authors's reply. *Lancet* 2013; 381 (9985): 2250. Wittebole X, Laterre P-F, **Opal SM**. Targeting TLR4 intracellular domain to prevent ischemic liver disease: An innovative approach or just a futuristic dream? *Critical Care Medicine*. 2013 (in press)

118. **Opal SM.** The current understanding of sepsis and research priorities for the future: special focus issue of Virulence on sepsis. *Virulence* 2013; 5(Nov): (in press)
119. **Pop-Vicas A,** Rosa Baier. Healthcare workers' hands and *Clostridium difficile* spores - making progress? *Infect Control Hosp Epidemiol* 2013, in press.
120. **Pop-Vicas A, Opal S.** The clinical impact of multidrug resistant-gram-negative bacilli in the management of septic shock. *Virulence* 2013, in press.
121. **Pop-Vicas A,** A. Chahin, D. Hagau, K. Chapin. Risk factors for prolonged H1N1 influenza in hospitalized patients. *Am J Infect. Control* 2013, Jul 27.
122. **Pop-Vicas A, Opal SM.** Over-distention of the airways by mechanical ventilation in the elderly: adding insult to injury. *Critical Care* 2013; 17:1-2 (4/July/2013)
123. **Pop-Vicas A,** E. Shaban, C. Letourneau, A. Pechie. Empiric antimicrobial prescriptions in patients with *Clostridium difficile* infections at hospital admission, and impact on clinical outcomes. *Infect Control Hosp Epidemiol.* 2012;33(11):1101-6.
124. **Pop-Vicas A,** S. Gravenstein, V. Mor. Policy Research Needs for Universal Influenza Vaccination of the Elderly. *Public Policy and Aging Report*, Fall 2012, Vol.22 Issue 4, p.26.
125. Gozalo P, **Pop-Vicas A,** Feng Z, Gravenstein S, Mor V. The impact of influenza on functional decline. *J Am Geriatr Soc.* 2012; 60(7):1260-7.
126. A. Ismail, **Pop-Vicas A, Opal SM.** Spinal Epidural Abscess. *Med Health R.I.* 2012; 95 (1): 21-2.
139. Gupta P, Lacksmith-Smith C, Snyder B, Ratner D, Rohan L, Patton D, **Ramratnam B,** Cole A. Antiviral Activity of Retrocyclin RC-101, a Candidate Microbicide Against Cell-Associated HIV-1. *AIDS Research & Human Retrovirus.* 29(2):391-6, 2013.
140. Quesenberry PJ, Dooner MS, Goldberg LR, Aliotta JM, Pereira M, Amaral A, Del Totto MM, Hixson DC, **Ramratnam B.** A new stem cell biology: the continuum and microvesicles. *Trans Am Clin Climatol Assoc.* 123:152-66, 2012.
141. Nijhawan AE, DeLong AK, Chapman S, **Rana A,** Kurpewski J, Ingersoll J, **Caliendo AM** and **Cu-Uvin S.** Effect of HSV-2 Suppressive Therapy on Genital Tract HIV-1 RNA Shedding among Women on HAART: a Pilot Randomized Controlled Trial. *Infectious Diseases in Obstetrics and Gynecology.* 2012;2012:868526 doi:1155/2012/868526.
142. Wilson I, Fowler FJ, Cosenza C, Michaud J, Bentkover J, **Rana A,** Kogelman L, Rogers W. Cognitive and field testing of a new set of medication adherence self-report items for HIV care. *AIDS and Behavior.* 2013 Sep 28 (Epub ahead of print). PMID: 24077970
143. Patel N, **Rana A,** Thomas A, Barnhart JC, **Flanigan TP, van den Berg JJ, Chan PA.** HIV Testing Practices among New England College Health Centers. *AIDS Research and Therapy.* 2013 Mar 18; 10(1):8. doi: 10.1186/1742-6405-10-8. PMID 23496891. PMCID:

144. Rahangdale L, Stewart A, Stewart R, Badell M, Levison J, Ellis P, Cohn S, Kempf M, Lazenby G, Tandont R, **Rana A**, Nguyen, Sturdevant M, Cohan D. Pregnancy Intentions among Women Living with HIV in the United States. *JAIDS* Manuscript in Press 2013
145. Triboulet S., Dubee V., Lecoq L., Bougault C., Mainardi J.L., **Rice L.B.**, Etheve-Quelquejeu M., Gutmann L., Marie A., Dubost L., Hugonnet J.E., Simorre J.P., Arthur M. Kinetic features of L,D-transpeptidase inactivation critical for lactam antibacterial activity. *PLoS One* 8:e67831, 2013.
146. **Rice L.B.**, Tait-Kamradt A. A novel genetic region flanks the plasmid-carried blaNDM-1 isolated from a patient in Rhode Island in 2012. *Antimicrob Agents Chemother* 57(8):4082-5, 2013.
147. **Rice L.B.** The complex dynamics of antimicrobial activity in the gastrointestinal tracts. *Trans Am Clin Clim Assoc.* 124:123-32, 2013.
148. Dubee V, Arthur M, Fief H, Triboulet S, Mainardi J.L., Gutmann L, Sollogoub M, **Rice L.B.**, Etheve-Quelquejeu M, Hugonnet J.E. Kinetic analysis of *Enterococcus faecium* L, D-transpeptidase inactivation by carbapenems. *Antimicrob Agents Chemother* 56(6):3409, 2012.
149. Papp-Wallace K.M., Senkfor B, Gatta J, Chai W, Taracila M.A., Shanmugasundaram V, Han S, Zaniewski R.P., Lacey B.M., Tomaras A.P., Skalweit M.J., Harris M.E., **Rice L.B.**, Buynak J.D., Bonomo R.A. Early insights into the interactions of different β -lactam antibiotics and β -lactamase inhibitors against soluble forms *Acinetobacter baumannii* PBP1a and *Acinetobacter* sp. PBP3. *Antimicrob Agents Chemother* 56(11):5687, 2012.
150. **Rice LB.** Mechanisms of Resistance and Clinical Relevance of Resistance to β -Lactams, Glycopeptides, and Fluoroquinolones. *Mayo Clin Proceed.* 87(2):198-208, 2012.
151. Hollenbeck B.L., **Rice L.B.** Intrinsic and acquired resistance mechanisms in enterococcus. *Virulence* 3(5): 421-433 Landers Bioscience, 2012.
152. **Rice L.B.**, Gastrointestinal bacteria will have its way. *J Infect Dis.* 206:1334-5, 2012.
153. Dumont DM, Allen SA, Brockmann B, Alexander NE, **Rich JD.** Incarceration, community health, and racial disparities. *J Health Care Poor Underserved* 24(1):78-8, 2013 (commentary) doi: 10.1353/hpu.2013.0000. PMID: 23377719
154. Beletsky L, Wall AY, **Rich JD.** Opioid Overdose Fatality Prevention. *JAMA* 309(9);873-4, 2013.
155. **Rich JD,** DiClemente R, Levy J, Lyda K, Ruiz M, Rosen DL, Dumont D. Correctional

facilities as partners in reducing HIV disparities. *JAIDS* 63(Suppl 1):S49-53, 2013 PMID: PMC3701159

156. Matusow H, Dickman SL, **Rich JD**, Fong C, Dumont DM, Hardin C, Marlowe D, Rosenblum A. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. *J Subst Abuse Treat.* 48(3):239-47, 2013. PMID: PMC3602216
157. Gordon MS, Kinlock TW, McKenzie M, Wilson ME, **Rich JD**. Rapid HIV testing for individuals on probation/parole: outcomes of an intervention trial. *AIDS Behav.* 2013;17(6):2022-30.
158. McNamara BC, Losikoff PT, Huguenin L, Macalino GE, **Rich JD**, **Gregory SH**. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. *J Urban Health* [Epub ahead of print, May 31, 2013]. NIHMSID: 487365 (in process).
159. Dumont DM, Gjelsvik A, Chen N, **Rich JD**. Hispanics, incarceration, and TB/HIV Screening: a missed opportunity for prevention. *J Immigrant Minority Health*, Published on line: January 5, 2013, DOI 10.1007/s10903-012-9764-6. PMID: 23292731 (in process).
160. Rosen DL, Dumont DM, Cislo AM, Brockmann BW, Traver A, **Rich JD**. Medicaid policies and practices in US state prison systems. *Am J Pub Health.* 2013 (in process)
161. Ahalt C, Trestman RL, **Rich JD**, Greifinger RB, Williams BA. Paying the price: the pressing need for quality, cost and outcomes data to improve correctional healthcare for older prisoners. *J American Geriatrics Society.* 2013 (in process)
162. Dumont DM, Gjelsvik A, Redmond N, Rich JD. Jail as public health partners: incarceration and disparities among medically underserved men. *Int'l J of Men's Health.* 2013 (in process)
163. Echenique IA, **Rich JD**. EFV/FTC/TDF-associated hepatotoxicity: a case report and review. *AIDS Pt Care STDs.* 2013 (in process)
164. Green TC, Ray M, Bowman SE, McKenzie M, **Rich JD**. Two cases of intranasal naloxone self-administration in opioid overdose. *Subst Abuse* NIHMSID: 516172 (in process).
165. Dumont DM, Brockmann B, Dickman S, Alexander N, **Rich JD**. Public health and the epidemic of incarceration. *Annu Rev Public Health* 33:325-39, 2012. PMID: PMC3329888
166. Lee JD, **Rich JD**. Opioid pharmacotherapy in criminal justice settings: now is the time. *Subst Abuse* 33(1):1-4, 2012.
167. Yokell MA, Green TC, **Rich JD**. Prescription drug monitoring programs *JAMA* 307(9):912-13, 2012.

168. **Rich JD**, Clarke JG, Adashi EY. Obstetrical and gynecological training in the correctional setting: learning to care for the most vulnerable patients. *J Grad Med Ed* DOI: <http://dx.doi.org/10.4300/JGME-D-12-00160.1>, September, 2012.
169. Beletsky L, **Rich JD**, Walley AY. Prevention of fatal opioid overdose. *JAMA* (viewpoint) 308(18):1863-4, 2012. PMID: PMC3551246
170. **Rich JD**. HIV/AIDS in America. *Science* (337):167-71, July 13, 2012. (special section).
171. Green TC, McGowan SK, Yokell MA, Pouget ER, **Rich JD**. HIV infection and risk of overdose: a systematic review and meta-analysis. *AIDS* 26(4): 403-17, 2012. PMID: PMC3329893
172. Glycogen Synthase Kinase 3 beta inhibits microRNA-183-96-182 cluster via the beta-Catenin/TCF/LEF1 pathway in gastric cancer cells: **Tang X**; Zheng, Dong; Hu, Ping; Zeng, Zongyue; **Li M**; Tucker, Lynne; Monahan, Renee; Resnick, Murray; Liu, Manran, **Ramratnam B**. *Nucleic Acids Research* (in press)
173. **Tang X**, Wen S, Zheng D, Tucker L, Cao L, Pantazatos D, Moss S, **Ramratnam B**. Acetylation of Drosha on the N-terminus Inhibits its Degradation by Ubiquitination. *PLoS ONE*. 29;8(8):e72503, 2013.
174. Kwei K, **Tang X**, Lok AS, Sureau C, Garcia T, Li J, Wands J, Tong S. Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. *J Virol*. 2013 Feb;87(4):2352-7.
175. Clark US, Cohen RA, Sweet LH, Gongvatana A, Devlin KN Hana GN, Westbrook NL, Mulligan RC, Jerskey BA, White TL, Navia B, **Tashima KT**. Effects of HIV and early life stress on amygdala morphometry and neurocognitive function. (2012) *J Int Neuropsychology Soc*. (4)657-68, PMID: 22621973
176. **Taylor LE**, Maynard MA, Friedmann PD, MacLeod CJ, **Rich JD**, **Flanigan TP**, Sylvestre DL. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients. *J Addict Med* 6(3):179-85, 2012. Doi: 10.1097/ADM.0b013e318257377f. PMID: 22614935
177. **Taylor LE**, Foont JA, Wurcel A, Linas B, Maynard MA, Chapman S, DeLong AK, **Cu-Uvin S**, Mayer KH. The Spectrum of Undiagnosed Hepatitis C Virus in a U.S. HIV Clinic. Accepted for publication, October 24, 2013. *AIDS Patient Care STDS*
178. **Taylor LE**, **Tashima KT**, **Cu-Uvin S**, Garg S, Chapman S, Westbrook ML. Hepatocellular carcinoma in HIV-infected women: two case reports. (2013) *R I Med J* (1)21-4, PMID: 23638454
179. Robaey G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stover H, Wedemeyer H, Schaefer M, **Taylor LE**, Backmund M, Dalgard O, Prins M, Dore GJ, and on behalf of the International Network on Hepatitis in Substance

- Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Clin Infect Dis*. 2013 Aug; 57 Suppl 2:S129-37 PMID: 23884061
180. **Taylor LE**, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis*. 2013 Aug;57 Suppl 2:S118-24. PMID: 23884059
181. Garg S, **Taylor LE**, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis*. 2013 May;56(10):1480-7. Epub 2013 Feb 5. PMID: 23386630
182. Grebely J, Oser M, **Taylor LE**, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. *J Infect Dis* 2013 Mar;207 Suppl 1:S19–25. PMID: 23390301
183. Brouwer MC, Thwaites GE, **Tunkel AR**, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. *Lancet* 2012;380:1684-1692.
184. van de Beek D, Brouwer MC, Thwaites GE, **Tunkel AR**. Bacterial meningitis: advances in treatment. *Lancet* 2012;380:1693-1702.
185. Venkatesan A, **Tunkel AR**, Bloch KC, Luring AS, Sejvar J, Bitnun A, Stahl JP, Mailles A, Drebot M, Rupprecht CE, Yoder J, Cope JR, Wilson MR, Whitley RJ, Sullivan J, Granerod J, Jones C, Eastwood K, Ward KN, Durrheim DN, Solbrig MV, Guo-Duong L, Glaser CA on behalf of the International Encephalitis Consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium. *Clin Infect Dis* 2013;57:1114-1128.
186. Rosengard C, Tannis C, Dove DC, **van den Berg JJ**, Lopez R, Stein LAR, et al. Family sources of sexual health information, primary messages, and sexual behavior of at-risk, urban adolescents. *Am J Health Educ*. 2012;43(2):83-92.
187. Fava JL, **van den Berg JJ**, Rosen RK, Salomon LA, Vargas S, Chistensen AL et al. Measuring self-efficacy to use vaginal microbicides: The Microbicide Use Self-Efficacy (MUSE) instrument. *Sex Health*. 2013 June 28. doi: 10.1071/SH13013. [Epub ahead of print]
188. Bock B, Lopes CE, **van den Berg JJ**, Roberts MB, Stein LAR, Martin RA, et al. Social support and smoking abstinence among incarcerated adults in the United States: a longitudinal study. *BMC Public Health*. 2013;13:859.
189. **van den Berg JJ**, Bock B, Roberts MB, Stein LAR, Friedmann PD, Martin SA et al. Cigarette smoking as an expression of independence and freedom among inmates in a tobacco-free prison in the United States. *Nicotine Tob Res*. 2013 Oct 22. doi: 10.1093/ntr/ntt163. [Epub ahead of print]

190. **van den Berg JJ**, Rosen RK, Bregman DE, Thompson LA, Jensen KJ, Kiser PF, et al. "Set it and forget it": Women's perceptions and opinions of long-acting topical vaginal gels. *AIDS Behav.* 2013 Nov 19. [Epub ahead of print]
191. Morrow KM, Underhill K, **van den Berg JJ**, Vargas S, Rosen RK, Katz DF. User-identified gel characteristics: A qualitative exploration of perceived product efficacy of topical vaginal microbicides. *Arch Sex Behav.* In press
192. **Zaller ND**, McKenzie M, McGowan S, Green TC, **Rich JD**. Initiation of buprenorphine during incarceration and linkage to treatment upon release. *J Subst Abuse Treat* 45:222-26, 2013. PMID: PMC3690138
193. Fu JJ, **Zaller ND**, Yokell MA, Bazazi AR, **Rich JD**. Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. *J Subst Abuse Treat* 44(5):502-5, 2013. PMID: PMC3695471
194. Larney S, **Zaller ND**, **Rich JD**. HIV prevention, treatment, and care for people who inject drugs. *J Infect Dis* (editorial commentary) [advance access DOI: 10.1093/infdis/jit167, May 7, 2013]. NIHMSID: 484425 (in process)
195. **Zaller ND**, Yokell MA, Nayak SM, Fu JJ, Bazazi AR, **Rich JD**. Syringe acquisition experiences and attitudes among injection drug users undergoing short-term opioid detoxification in Massachusetts and Rhode Island. *J Urban Health* 89(4):659-70, 2012. PMID: 22427232
196. Yokell MA, **Zaller ND**, Green TC, McKenzie M, **Rich JD**. Intravenous use of illicit buprenorphine/naloxone to reverse an acute opioid overdose. *J Opioid Manag* 8(1):63-6, 2012. PMID: PMC3343634
197. **Ziakas PD**, Kourbeti I, **Mylonakis E**. Systemic Antifungal Prophylaxis after Hematopoietic Stem Cell Transplantation: A meta-analysis. *Clin Ther.* (in press)
198. Prodromou ML, **Ziakas PD**, Poulou LS, Karsaliakos P, Thanos L, **Mylonakis E**. FDG-PET is a robust tool for the diagnosis of spondylodiscitis: A meta-analysis of diagnostic data. *Clin Nucl Med.* (in press)
199. **Ziakas PD**, Prodromou ML, El Khoury J, Zintzaras E, **Mylonakis E**. The Role of TLR4 896 A>G and 1196 C>T in Susceptibility to Infections: A Review and Meta-Analysis of Genetic Association Studies. *PLOS One* 2013 [In press]
200. **Ziakas PD**, Anagnostou T, **Mylonakis E**. The Prevalence and Significance of Methicillin-Resistant Staphylococcus aureus Colonization at Admission in the General ICU Setting: A Meta-Analysis of Published Studies. *Crit Care Med.* 2013 Oct 18. [Epub ahead of print] PubMed PMID: 24145849

201. **Ziakas PD**, Thapa R, **Rice LB**, **Mylonakis E**. Trends and Significance of VRE Colonization in the ICU: A Meta-Analysis of Published Studies. *PLoS One*. 2013 Sep 27;8(9):e75658. doi: 10.1371/journal.pone.0075658. PubMed PMID: 24086603; PubMed Central PMCID: PMC3785502
202. **Ziakas PD**, Karsaliakos P, Prodromou ML, **Mylonakis E**. Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies. *Biomarkers*. 2013 Sep 23. [Epub ahead of print] PubMed PMID: 24059848
203. Hadjigeorgiou GM, Doxani C, Miligkos M, **Ziakas P**, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. *J Clin Pharm Ther*. 2013 Aug 20. doi: 10.1111/jcpt.12090. [Epub ahead of print] PubMed PMID: 23957759
204. Omer AK, **Ziakas PD**, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Attar E, Chen YB, Spitzer TR, **Mylonakis E**, Ballen KK. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. *Biol Blood Marrow Transplant*. 2013 Aug;19(8):1190-6. doi: 10.1016/j.bbmt.2013.05.018. Epub 2013 Jun 5. PubMed PMID: 23747459
205. Hatzis G, **Ziakas PD**, Kavantzias N, Triantafyllou A, Sigalas P, Andreadou I, Ioannidis K, Chatzis S, Filis K, Papalampros A, Sigala F. Melatonin attenuates high fat diet-induced fatty liver disease in rats. *World J Hepatol*. 2013 Apr 27;5(4):160-9. doi: 10.4254/wjh.v5.i4.160. PubMed PMID: 23671720; PubMed Central PMCID: PMC3648647
206. Xyla V, Skopelitis E, **Ziakas PD**, Kontos A, Ioannidis E, Kordosis T, Aroni K. PGP 9.5 neuronal marker may differentiate immunohistochemically HIV-related from Mediterranean and immunosuppression-associated Kaposi's sarcoma. *Arch Dermatol Res*. 2013 May 14. [Epub ahead of print] PubMed PMID: 23670173
207. Poulou LS, Tsagouli P, **Ziakas PD**, Politi D, Trigidou R, Thanos L. Computed tomography-guided needle aspiration and biopsy of pulmonary lesions: a single-center experience in 1000 patients. *Acta Radiol*. 2013 Jul;54(6):640-5. doi: 10.1177/0284185113481595. Epub 2013 Apr 30. PubMed PMID: 23528565